German billionaire investor Christian Angermayer is staking his latest business venture on a proposition that has alarmed much of the sporting establishment: that the future of elite competition lies in the open use of performance-enhancing drugs under medical supervision.

Angermayer, whose investments have spanned biotechnology, cryptocurrencies and psychedelic medicine, is a leading supporter of the Enhanced Games, a controversial sporting event that permits athletes to use substances prohibited under conventional anti-doping rules.

Critics have labeled the project the “Steroid Olympics,” while its organizers argue it represents a new model for sport, health and human performance.The inaugural competition is scheduled to feature sprinting, swimming and weightlifting events.

Organizers say participating athletes will compete under a framework that allows the use of performance-enhancing substances, provided they are medically monitored.

According to data cited by Enhanced Games organizers, 36 of the 42 athletes entered in the event participated in a study examining drug use. Of those athletes, all but two reportedly used substances banned by traditional anti-doping authorities.

Organizers said 91% used testosterone, 79% human growth hormone, 41% erythropoietin (EPO) and 29% anabolic steroids.The figures underscore why the initiative has generated strong opposition from many sporting bodies, anti-doping officials and health experts, who have long warned about the risks associated with performance-enhancing drugs.

The Enhanced Games, however, argues that existing anti-doping systems have failed to eliminate drug use and that regulated enhancement offers a more transparent alternative.For Angermayer, the venture extends beyond sport.

He views the competition as a platform for broader acceptance of medical interventions aimed at improving performance, appearance and quality of life.Speaking about the concept, Angermayer questioned why medical treatments should be confined to addressing illness.

He argued that medically approved therapies supervised by physicians could be used proactively to help individuals achieve personal goals, whether related to athletic performance, aging or general well-being.The Enhanced Games business model reflects that philosophy.

Organizers hope public exposure to athletes openly using enhancement therapies could increase consumer interest in products marketed for performance, recovery and longevity. Among the products promoted through the broader ecosystem are testosterone-based treatments and peptide therapies associated with skin health and physical performance.

Supporters of the project argue that advances in biotechnology are already transforming medicine and that sport should adapt accordingly. Critics counter that normalizing performance-enhancing drugs risks encouraging unsafe use among amateur athletes and the broader public, particularly younger people who may seek competitive advantages without adequate medical oversight.

Angermayer remains convinced that public opinion will shift. He predicts the event will attract a large and politically diverse audience, introducing new consumers to enhancement therapies and challenging long-standing assumptions about anti-doping policies.

The billionaire’s confidence is consistent with his reputation for pursuing unconventional investments. Beyond biotechnology and financial markets, Angermayer is known for collecting rare fossils and dinosaur remains.

During a discussion of his collection, he described owning what he said is the largest triceratops skull ever discovered and also possessing a Tyrannosaurus rex skeleton that he may sell for approximately $40 million.He said the triceratops skull is being installed in his London apartment, a process complicated by insurance requirements and the logistical challenge of moving such a large specimen into a residential property.

Yet even by Angermayer’s standards, the Enhanced Games may be his most ambitious undertaking. The initiative seeks to challenge decades of anti-doping norms that have shaped modern international sport, including policies enforced by organizations such as World Anti-Doping Agency and numerous international federations.

Supporters argue that technological and medical advances make traditional distinctions between natural and enhanced performance increasingly difficult to maintain. Opponents respond that the widespread acceptance of enhancement drugs would fundamentally alter the nature of athletic competition and increase pressure on athletes to use substances simply to remain competitive.

Angermayer believes the concept can eventually expand beyond current participants. He has suggested future editions could include well-known former athletes in their 40s and 50s attempting to approach performances from their competitive prime with the assistance of enhancement therapies.

Such proposals remain highly controversial and are likely to face continued scrutiny from sports governing bodies and medical experts. Questions surrounding athlete safety, informed consent, competitive fairness and the commercial promotion of enhancement drugs remain central to the debate.Despite those concerns, Angermayer appears undeterred.

He argues that enhancement technologies represent an inevitable part of the future and sees the Enhanced Games as an early step toward broader public acceptance of performance-focused medicine.Whether that vision gains mainstream support remains uncertain.

The project’s long-term viability will likely depend on audience interest, athlete participation, regulatory responses and the public’s willingness to embrace a model of sport built around openly enhanced performance.For now, Angermayer is placing a high-stakes wager that the concept will endure.

While skeptics question whether the Enhanced Games can survive beyond its initial years, the entrepreneur insists the movement is only beginning.